NCT00101829View on ClinicalTrials.gov

Anti-CD20 Antibody Therapy for Sjogren's Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2009

Conditions
Sjogren's Syndrome
Interventions
DRUG

Rituximab

1000 mg intravenous infusion

Trial Locations (2)

27710

Duke University Medical Center, Durham

19104-6160

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

Autoimmunity Centers of Excellence

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00101829 - Anti-CD20 Antibody Therapy for Sjogren's Syndrome | Biotech Hunter | Biotech Hunter